Alimena G - Search Results

1

Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.

Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Levi A, Cartoni C, Musto P, Alimena G. Federico V, et al. Among authors: alimena g. Clin Adv Hematol Oncol. 2012 Apr;10(4):266-8. Clin Adv Hematol Oncol. 2012. PMID: 22706491 No abstract available.

2

Isolated myeloid sarcoma without bone marrow involvement.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Clin Adv Hematol Oncol. 2012 Jan;10(1):66-7. Clin Adv Hematol Oncol. 2012. PMID: 22398813 Review. No abstract available.

3

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Curr Drug Targets. 2009 Jun;10(6):530-6. doi: 10.2174/138945009788488468. Curr Drug Targets. 2009. PMID: 19519355 Review.

4

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Crit Rev Oncol Hematol. 2011 Aug;79(2):135-43. doi: 10.1016/j.critrevonc.2010.07.003. Epub 2010 Aug 4. Crit Rev Oncol Hematol. 2011. PMID: 20685131 Review.

5

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935. Expert Opin Drug Saf. 2010. PMID: 20722490 Review.

6

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Ther Targets. 2010 Nov;14(11):1157-76. doi: 10.1517/14728222.2010.522570. Expert Opin Ther Targets. 2010. PMID: 20858024 Review.

7

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.

Alimena G, Breccia M, Musto P, Cilloni D, D'Auria F, Latagliata R, Sanpaolo G, Gottardi E, Saglio G, Mandelli F. Alimena G, et al. Leuk Res. 2011 Apr;35(4):504-7. doi: 10.1016/j.leukres.2010.08.021. Epub 2010 Oct 23. Leuk Res. 2011. PMID: 20971509 Clinical Trial.

8

Nilotinib and dasatinib first-line: are we ready for imatinib replacement?

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2011 Sep;35(9):1153-5. doi: 10.1016/j.leukres.2011.02.004. Epub 2011 Feb 25. Leuk Res. 2011. PMID: 21353701 No abstract available.

9

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. BioDrugs. 2011. PMID: 21528941 Review.

10

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Pharmacother. 2011 Sep;12(13):2075-87. doi: 10.1517/14656566.2011.597741. Epub 2011 Jul 1. Expert Opin Pharmacother. 2011. PMID: 21721847 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters